Clinical trial
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of…
NCT00495391 · Romark Laboratories L.C., Industry · Completed
Key facts
| NCT number | NCT00495391 |
|---|---|
| Title | Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C |
| Official title | Phase II, Randomized, Double-blind, Placebo-controlled Study of Nitazoxanide in Combination With Peginterferon Alfa-2a and Ribavirin in Patients With Hepatitis C Who Have Failed to Respond to a Prior Course of Peginterferon and Ribavirin |
| Acronym | STEALTHC-2 |
| Lead sponsor | Romark Laboratories L.C., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C |
| Intervention type | Biological, Drug |
| Interventions | Nitazoxanide, Placebo, Peginterferon alfa-2a, Ribavirin |
| Enrollment | 64 |
| Start date | Jul 1, 2007 |
| Primary completion | Feb 1, 2010 |
| Completion | Feb 1, 2010 |
| First posted | Jul 3, 2007 |
| Last update posted | May 8, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: